Financial Solutions Advisory Group Inc. Takes $1 Million Position in Zoetis Inc. $ZTS

Financial Solutions Advisory Group Inc. acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) in the 1st quarter, Holdings Channel.com reports. The fund acquired 8,481 shares of the company’s stock, valued at approximately $1,003,000.

Several other institutional investors have also recently made changes to their positions in the company. Allen Capital Group LLC grew its holdings in Zoetis by 5.0% during the 1st quarter. Allen Capital Group LLC now owns 40,103 shares of the company’s stock valued at $4,741,000 after purchasing an additional 1,926 shares during the last quarter. Glenmede Trust Co. NA lifted its stake in Zoetis by 36.5% in the first quarter. Glenmede Trust Co. NA now owns 231,874 shares of the company’s stock worth $27,410,000 after purchasing an additional 62,034 shares during the last quarter. Axiom Investment Management LLC bought a new stake in Zoetis in the first quarter worth about $99,000. Summitry LLC purchased a new position in shares of Zoetis during the first quarter valued at approximately $21,255,000. Finally, Segall Bryant & Hamill LLC purchased a new position in shares of Zoetis during the first quarter valued at approximately $10,036,000. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on ZTS shares. JPMorgan Chase & Co. reduced their price target on Zoetis from $190.00 to $130.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Stifel Nicolaus dropped their price objective on Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a report on Friday, June 26th. Argus reaffirmed a “hold” rating on shares of Zoetis in a research report on Wednesday, May 27th. HSBC reduced their target price on Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Finally, Morgan Stanley decreased their target price on Zoetis from $115.00 to $99.00 and set an “overweight” rating for the company in a research report on Wednesday, July 22nd. Eight research analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Zoetis presently has an average rating of “Hold” and an average target price of $118.33.

Zoetis Price Performance

Shares of ZTS stock opened at $77.37 on Friday. The company has a market capitalization of $32.44 billion, a P/E ratio of 12.83, a P/E/G ratio of 1.21 and a beta of 0.75. The company’s 50-day simple moving average is $77.05 and its two-hundred day simple moving average is $102.49. Zoetis Inc. has a one year low of $71.47 and a one year high of $160.48. The company has a debt-to-equity ratio of 2.80, a current ratio of 3.15 and a quick ratio of 1.91.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a net margin of 27.80% and a return on equity of 66.85%. The company had revenue of $2.26 billion for the quarter, compared to the consensus estimate of $2.30 billion. During the same period in the prior year, the firm posted $1.48 EPS. The business’s revenue was up 2.9% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. As a group, equities analysts anticipate that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be issued a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.7%. Zoetis’s payout ratio is currently 35.16%.

Insider Transactions at Zoetis

In other Zoetis news, Director Paul Bisaro acquired 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 13th. The shares were bought at an average cost of $75.88 per share, with a total value of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares in the company, valued at $2,114,168.56. This represents a 7.73% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Michael B. Mccallister acquired 3,000 shares of Zoetis stock in a transaction that occurred on Monday, May 11th. The stock was acquired at an average cost of $77.76 per share, with a total value of $233,280.00. Following the purchase, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. This represents a 13.94% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders acquired 11,650 shares of company stock valued at $886,384. Company insiders own 0.22% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.